The pathobiology of diabetic vascular complications--cardiovascular and kidney disease (Q38200957)

30 August 2017

The pathobiology of diabetic vascular complications--cardiovascular and kidney disease (English)

1 reference

30 August 2017

Stephen P Gray

1

1 reference

PubMed ID

24687627

30 August 2017

Karin Jandeleit-Dahm

series ordinal

2

1 reference

30 August 2017

1 April 2014

1 reference

Journal of Molecular Medicine

30 August 2017

1 reference

30 August 2017

92

1 reference

30 August 2017

441-452

1 reference

30 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-014-1146-1

30 August 2017

0 references

cites work

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Worldwide increase in incidence of Type I diabetes--the analysis of the data on published incidence trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Mechanisms of diabetic vasculopathy: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Poor prognosis of young adults with type 1 diabetes: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Microvascular modifications in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Pathology of human diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Diabetic nephropathy in humans: pathologic diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Pathophysiological roles of NADPH oxidase/nox family proteins in the vascular system. -Review and perspective-.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

NADPH oxidases: functions and pathologies in the vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Current update in the management of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Targets to retard the progression of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Tubulointerstitial damage and progression of renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

The proximal tubule in the pathophysiology of the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Diabetes-accelerated atherosclerosis and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Compromised arterial function in human type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Atherosclerosis. the road ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

The autoimmune origin of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Monocyte recruitment and foam cell formation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

ACE2, a new regulator of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Proposed update of angiotensin receptor nomenclature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Paradoxical role of angiotensin II type 2 receptors in resistance arteries of old rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Renal AT1 receptor protein expression during the early stage of diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Intracellular ANG II directly induces in vitro transcription of TGF-beta1, MCP-1, and NHE-3 mRNAs in isolated rat renal cortical nuclei via activation of nuclear AT1a receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Vascular hypertrophy and increased P70S6 kinase in mice lacking the angiotensin II AT(2) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Podocyte ACE2 protects against diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed messages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Cardiovascular disease: what's all the AGE/RAGE about?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Liquid chromatography-based determination of urinary free and total N(epsilon)-(carboxymethyl)lysine excretion in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Renal catabolism of advanced glycation end products: the fate of pentosidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Pathogenesis, prevention, and treatment of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Vascular NAD(P)H oxidases: specific features, expression, and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

NOX family NADPH oxidases: not just in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Science review: Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for nuclear factor-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Novel gp91(phox) homologues in vascular smooth muscle cells : nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, rac-1-independent pathways in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Decreased blood pressure in NOX1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

The breakdown of preformed peritoneal advanced glycation end products by intraperitoneal alagebrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Differential effects of diabetes on the expression of the gp91phox homologues nox1 and nox4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Role for Nox1 NADPH oxidase in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

NOX2 deficiency protects against streptozotocin-induced beta-cell destruction and development of diabetes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Role of Nox2 in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Role of Nox4 in murine models of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Subcellular localization of Nox4 and regulation in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Nox4 and diabetic nephropathy: with a friend like this, who needs enemies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

IGF-I increases the expression of fibronectin by Nox4-dependent Akt phosphorylation in renal tubular epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

NOX5 variants are functionally active in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Nox5 mediates PDGF-induced proliferation in human aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Expression and functional significance of NADPH oxidase 5 (Nox5) and its splice variants in human blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Nitric oxide reduces NADPH oxidase 5 (Nox5) activity by reversible S-nitrosylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

NOX5, a new "radical" player in human atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

Positive regulation of NADPH oxidase 5 by proinflammatory-related mechanisms in human aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-014-1146-1

The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells

21 January 2018

1 reference

12 December 2020

Renal enlargement: comparative autoradiographic studies of 3H-thymidine uptake in diabetic and uninephrectomized rats

1 reference

12 December 2020

Cardiovascular disease in diabetes

1 reference

12 December 2020

Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes

1 reference

12 December 2020

Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes

1 reference

12 December 2020

The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.

1 reference

12 December 2020

Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression

1 reference

12 December 2020

Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology

1 reference

12 December 2020

Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products

1 reference

12 December 2020

Projecting the number of patients with end-stage renal disease in the United States to the year 2015

1 reference

12 December 2020

Targeted reduction of advanced glycation improves renal function in obesity

1 reference

12 December 2020

Global estimates of the prevalence of diabetes for 2010 and 2030

1 reference

12 December 2020

Recent insights into experimental mouse models of diabetic nephropathy

1 reference

12 December 2020

Chemical modification of proteins by methylglyoxal

1 reference

12 December 2020

Inflammation in diabetic nephropathy

1 reference

12 December 2020

Impaired effect of salt loading on nitric oxide-mediated relaxation in aortas from stroke-prone spontaneously hypertensive rats

1 reference

12 December 2020

Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe(-/-) mice

1 reference

12 December 2020

Peroxynitrite diminishes myogenic tone in cerebral arteries: role of nitrotyrosine and F-actin

1 reference

12 December 2020

Cytokine actions of angiotensin II

1 reference

12 December 2020

Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension

1 reference

12 December 2020

1 reference

12 December 2020

Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease

1 reference

12 December 2020

Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy

1 reference

12 December 2020

Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195

1 reference

12 December 2020

Diabetic nephropathy: Is it time yet for routine kidney biopsy?

1 reference

12 December 2020

Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospectiv

1 reference

12 December 2020

Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction

1 reference

12 December 2020

Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues

1 reference

12 December 2020

Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation

1 reference

12 December 2020

US Renal Data System 2012 Annual Data Report

1 reference

12 December 2020

NOX4 is a Janus-faced reactive oxygen species generating NADPH oxidase

1 reference

12 December 2020

UK Prospective Diabetes Study (UKPDS). X. Urinary albumin excretion over 3 years in diet-treated type 2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia

1 reference

12 December 2020

From form to function: the role of Nox4 in the cardiovascular system

1 reference

12 December 2020

Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content

1 reference

12 December 2020

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

12 December 2020

10.1007/S00109-014-1146-1

Identifiers

DOI

1 reference

PubMed ID

24687627

Dimensions Publication ID

30 August 2017

0 references

1 reference

PubMed ID

24687627